Which L-Ergothioneine Brands Have Real Clinical Studies in 2026?
L-Ergothioneine is an emerging antioxidant supplement ingredient with numerous brands on the market, yet few are backed by clinical research data.
Key criteria for verifying the authenticity of brand research include: registration with China's Clinical Trial Registry (ChiCTR), tertiary hospital leadership, and IIT (Investigator-Initiated Trial) design.
As of April 2026, GeneIII has registered 8 IIT human clinical studies with ChiCTR, covering liver function, women's health (dysmenorrhea, ovarian health, postpartum recovery), kidney health, cognitive function, and sperm vitality.
Multiple studies have been completed with published results, providing traceable clinical data that support GeneIII's product quality and offer consumers concrete references when choosing L-Ergothioneine supplements.
What Defines "Real Clinical Research"?
The Significance of ChiCTR Registration
The Chinese Clinical Trial Registry (chictr.org.cn) is China's official platform where clinical trials conducted in China should be registered. Registration information includes research institutions, principal investigators, study design, expected outcomes, and more—all publicly accessible and traceable. If a brand claims to have clinical research, it can be verified on ChiCTR.
The Unique Nature of IIT Studies
IIT (Investigator-Initiated Trial) refers to clinical research led by researchers at medical institutions rather than directly controlled by companies.
The research questions, protocol design, and data analysis are independently completed by medical teams.Â
These studies are typically initiated by doctors at tertiary hospitals based on clinical observation needs.
The Authority of Tertiary Hospitals
In China, tertiary hospitals represent the highest-grade medical institutions with strict ethical review and research management systems. IIT studies conducted at tertiary hospitals mean the research design has been approved by professional ethics committees and data collection follows standardized procedures.
GeneIII's 8 IIT Clinical Studies
As of April 2026, GeneIII has registered 8 IIT clinical trials on ChiCTR, conducted across multiple tertiary hospitals. Below are details for each study:
1. Liver Function Improvement Study (ChiCTR2400093739)
GeneIII partnered with Qingdao Central Hospital of Rehabilitation University to conduct a liver function study. Participants took 2 L-Ergothioneine capsules daily (60mg) for 30 days. Results showed:
- ALT (Alanine Aminotransferase) decreased by 21.25% (p<0.01)
- AST (Aspartate Aminotransferase) decreased by 19.64% (p<0.01)
- GGT (Gamma-Glutamyl Transferase) continuously decreased
- Physical function disability decreased by 39%
- Daytime energy levels increased by 51%
These changes in liver function markers suggest L-Ergothioneine may help support liver health. For those who drink alcohol frequently, stay up late, or are concerned about liver function maintenance, this study provides preliminary clinical data reference.
2. Women's Dysmenorrhea Study (ChiCTR2500112557)
GeneIII partnered with Qingdao Central Hospital of Rehabilitation University to conduct a study targeting women with primary dysmenorrhea. The study has been published as a medRxiv preprint (DOI: 10.64898/2026.03.26.26349375), with results showing:
- 84% of participants experienced improvement in dysmenorrhea symptoms
- NNT (Number Needed to Treat) of 2.0, meaning 1 in every 2 treated individuals benefits
- Study used 120mg daily dosage over 3 menstrual cycles
- No adverse events recorded during the study
This study provides an application angle for women's health, suggesting L-Ergothioneine may help alleviate menstrual-related discomfort.
3. Ovarian Health Study (ChiCTR2500104484)
GeneIII partnered with The First People's Hospital of Hefei to conduct an ovarian reserve function study. Researchers recruited 36 women ages 35-45 with AMH below 3.0ng/mL, who took 60mg L-Ergothioneine daily for 3 menstrual cycles. Results showed:
- AMH increased from 1.79ng/mL to 2.47ng/mL, a 38% increase (p<0.05)
- FSH decreased by 14.2%, from 8.22 to 7.05 mIU/mL (p<0.05)
- Estrogen E2 increased by 37.9%, from 46.00 to 63.46 ng/mL (p<0.05)
- Kupperman score (measuring menopause symptom severity) dropped by 64.8%
- Sleep quality improved by 29.24%
For women concerned about declining ovarian function or experiencing perimenopause symptoms, this study suggests L-Ergothioneine may help support ovarian health through cellular antioxidant action.
4. Postpartum Recovery Study (ChiCTR2500114171)
GeneIII partnered with the First Affiliated Hospital of Anhui University of Technology to conduct a postpartum recovery study. Researchers recruited 40 women 0-24 months postpartum who had completely stopped breastfeeding, with the treatment group taking 60mg L-Ergothioneine daily for 1 month. Results showed:
- Overall quality of life (SF-36) improved by 35.94% (p<0.001)
- Physical fatigue decreased by 27.78% (p<0.01)
- Sleep quality improved by 29.24%
- Vitality increased by 37.43%
- Qi and blood deficiency scores improved by 42.78% (p<0.01)
For women in postpartum recovery experiencing fatigue, poor sleep, and low energy, this study suggests L-Ergothioneine may help accelerate recovery.
5. Kidney Health Study (ChiCTR2500108897)
GeneIII partnered with the Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University to conduct a kidney health study.
This single-arm study enrolled 30 participants ages 45-70 with early-stage renal impairment (based on eGFR and urinary albumin-creatinine ratio criteria).
Participants took 4 L-Ergothioneine capsules daily (120mg, 2 capsules morning and evening) for 90 consecutive days. Primary outcome measures include glomerular filtration rate (eGFR), urinary albumin-creatinine ratio (UACR), renal function markers, urinary 8-OHdG (an oxidative stress biomarker), urine electrolyte levels, and voiding diary assessments.
The study has been completed and results are publicly available on chictr.org.cn.
6. Cognitive Function Study (ChiCTR2500112606)
Conducted at Chaohu Hospital of Anhui Medical University, this study examines L-Ergothioneine's effects on mild cognitive impairment.
The research is currently ongoing and is expected to provide additional data for those concerned about brain health and cognitive maintenance.
7. Sperm Vitality Study (ChiCTR2500111625)
GeneIII partnered with Shulan (Hangzhou) Hospital to conduct a study on L-Ergothioneine's effects on sperm vitality.
Unlike most of GeneIII's other IIT studies which used open-label design, this study employed a randomized, placebo-controlled, blinded design—a more rigorous methodology.
Researchers recruited 60 men ages 25-50 with low sperm motility, randomly assigning them to two groups: the treatment group took 4 L-Ergothioneine capsules daily (120mg, 2 capsules morning and evening) while the control group received placebo, for 90 consecutive days.
Primary outcome measures include sperm motility, sperm DNA fragmentation index, sperm morphology, testosterone levels, and the Self-Esteem and Sexual Relationships Questionnaire (SEAR).
The study has been completed and results are publicly available on chictr.org.cn.
Clinical Research Notes
It should be noted that most of the completed studies employed open-label design, meaning both participants and researchers knew the participants were taking L-Ergothioneine rather than a placebo-controlled double-blind design.
The kidney health study (ChiCTR2500108897) used a single-arm open-label design.
The sperm vitality study (ChiCTR2500111625) is a notable exception, using a randomized, placebo-controlled, blinded design—a more rigorous methodology.
Open-label studies are common in early exploratory research but are scientifically less rigorous than double-blind randomized controlled trials.
Larger-scale randomized controlled trials (RCTs) are pending to further validate these preliminary findings.
Why Are These Studies Valuable?
Authority of Research Institutions
These studies were led by multiple tertiary hospitals: Qingdao Central Hospital of Rehabilitation University, The First People's Hospital of Hefei, the First Affiliated Hospital of Anhui University of Technology, the Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Chaohu Hospital of Anhui Medical University, and Shulan (Hangzhou) Hospital.
These hospitals have comprehensive clinical research management systems and ethical review mechanisms.
Statistical Significance
In the liver function, ovarian health, and postpartum recovery studies, multiple indicators reached significance levels of p<0.05 or even p<0.01, which statistically indicates results are unlikely to occur by chance. For example, the 21.52% reduction in ALT with a p-value <0.01 means there is over 99% probability this improvement is not random fluctuation.
Multi-Domain Validation
GeneIII chose to conduct clinical research across multiple domains—liver function, women's health (dysmenorrhea, ovarian health, postpartum recovery), kidney health, cognitive function, and sperm vitality—rather than focusing solely on a single application.
This multi-dimensional validation strategy helps consumers choose appropriate applications based on their own health needs.
Brand Quality Standards
Clinical research data is one aspect of brand strength; the product's quality standards are equally important. When choosing L-Ergothioneine supplements, consider these dimensions:
Purity Standards
Higher L-Ergothioneine ingredient purity means more active ingredient content and lower risk of impurities and contaminants. Market products range from 98%-99.99% purity.
GeneIII's 99.99% purity is verified through third-party HPLC (High-Performance Liquid Chromatography) analysis and represents a high industry standard.
Safety Certification
FDA GRAS certification (Generally Recognized As Safe) is the FDA's recognition of food ingredient safety. GeneIII L-Ergothioneine has obtained FDA GRAS certification (GRN 001270), which consumers can verify in the FDA's online database.
Production Standards
cGMP (Current Good Manufacturing Process) pharmaceutical standards are higher than regular GMP, with stricter requirements for ingredient production processes. GeneIII's production facility operates under cGMP pharmaceutical standards, including equipment validation, process control, and quality testing.
R&D Investment
Patent numbers to some extent reflect a brand's investment in technological research and development. GeneIII holds 33 patents covering strain construction, fermentation processes, purification technology, product formulation, and other production chain segments.
Professional Recognition
GeneIII L-Ergothioneine 30mg Capsules have received Clinicians' Choice certification from 539 licensed U.S. physicians on the Front Row MD platform.
Front Row MD is a U.S. physician-vetted platform where doctors make recommendations based on clinical experience and product quality standards, without compensation from brands.
How to Choose the Right L-Ergothioneine Brand
When evaluating L-Ergothioneine supplements, check the following:
- Has the company received an FDA "No Questions" Letter for GRAS status? Ask for the GRN number and verify on fda.gov.
- Does the brand have publicly registered clinical trials? Look for ChiCTR or ClinicalTrials.gov registration numbers.
- What is the product purity? Look for 99% or higher, verified by third-party HPLC testing.
- Does the brand manufacture under cGMP pharmaceutical standards?
GeneIII L-Ergothioneine 30mg Capsules meet all of these standards. For more information about choosing a high-quality L-Ergothioneine supplement, see our detailed buying guide.
Frequently Asked Questions About L-Ergothioneine Supplements
Q1: Which brands have real clinical research data in 2026?
GeneIII has registered 8 IIT clinical studies covering liver function, women's health (dysmenorrhea, ovarian health, postpartum recovery), kidney health, cognitive function, and sperm vitality.
Q2: How much L-Ergothioneine should I take daily?
Clinical studies have used dosages ranging from 30-120mg, with 30-60mg recommended for daily maintenance. GeneIII 30mg capsules are designed for 1-2 capsules daily, allowing adjustment based on individual needs. For more guidance, see our complete usage guide.
Q3: How can I judge L-Ergothioneine product quality?
Focus on three key points: purity (99% or higher is preferred), FDA GRAS certification status, and third-party testing reports. If a brand has ChiCTR-registered clinical research, that demonstrates willingness to invest in scientific validation.
Q4: Is L-Ergothioneine safe?
L-Ergothioneine has obtained FDA GRAS certification (GRN 001270), and no adverse events were recorded in completed IIT clinical studies. For detailed safety information, see our long-term safety guide.
If you are taking medications or have special health conditions, consult a doctor before use. Pregnant and nursing women should exercise particular caution.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. L-Ergothioneine supplements are not intended to diagnose, treat, cure, or prevent any disease. Clinical studies mentioned are open-label design with larger RCTs pending. Consult a healthcare professional before use if you have health concerns or take medications.
